Trial reportEuropean journal of cancer (Oxford, England : 1990)2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Trial report in European journal of cancer (Oxford, England : 1990), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.BMC cancer · 2022Pooled it
- Unraveling the role of deuterium in cancer: mechanisms, detection techniques, and therapeutic potential.Molecular diversity · 2026Review
- Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Frontiers in immunology · 2025Review
- Targeting c-Met in Cancer Therapy: Unravelling Structure-activity Relationships and Docking Insights for Enhanced Anticancer Drug Design.Current topics in medicinal chemistry · 2025Review
- The Treatment of Metastatic Renal Cell Carcinoma.Deutsches Arzteblatt international · 2024Review
- Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.Cureus · 2023Review
- Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost.International journal of molecular sciences · 2022Review
- Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.Drug design, development and therapy · 2022Review
- A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Editorial Commentary:Annals of translational medicine · 2020Article
- Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present).Molecules (Basel, Switzerland) · 2020Review
- Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.Acta pharmaceutica Sinica. B · 2020Article
- Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.Cancers · 2019Review
- Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".International journal of molecular sciences · 2019Review
- Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives.International journal of nephrology and renovascular disease · 2019Review
- Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.Cancer management and research · 2019Article
- Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.Ochsner journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951-09-902) provided access to tivozanib for patients who progressed on sorafenib in TIVO-1, comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC).
methodsPatients enrolled in this single-arm, phase 2 crossover study were previously randomised to sorafenib on TIVO-1, progressed and then crossed over to tivozanib. Patients received tivozanib (1.5 mg/day orally; 3 weeks on/1 week off) within 4 weeks after their last sorafenib dose.
findingsCrossover patients were exposed to tivozanib for a median of eight cycles. From the start of tivozanib treatment, median progression-free survival was 11.0 months (95% confidence interval [CI]: 7.3-12.7) and median overall survival was 21.6 months (95% CI: 17.0-27.6). Best overall response was partial response in 29 (18%) patients and stable disease in 83 (52%) patients, with a median duration of response of 15.2 and 12.7 months, respectively. About 77% of patients experienced adverse events, most frequently hypertension (26%), followed by diarrhoea (14%) and fatigue (13%); 53% of patients had treatment-related adverse events, including 24% grade ≥3. About 9% and 16% of patients had dose reductions and dose interruptions due to adverse events, respectively. A total of 30% of patients had serious adverse events, and 4% had treatment-related serious adverse events.
interpretationThis crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.